Get the Stockscreener App
3.93
3.15%
0.12
Karyopharm Therapeutics Inc stock is traded at $3.93, with a volume of 64,132.
It is up +3.15% in the last 24 hours and down -9.86% over the past month.
Karyopharm Therapeutics Inc is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with heavily pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. The company derives its revenue from United States.
See More
Previous Close:
$3.81
Open:
$3.71
24h Volume:
64,132
Relative Volume:
0.57
Market Cap:
$33.95M
Revenue:
$140.46M
Net Income/Loss:
$-146.34M
P/E Ratio:
-3.0945
EPS:
-1.27
Net Cash Flow:
$-117.73M
1W Performance:
-9.66%
1M Performance:
-9.86%
6M Performance:
-57.88%
1Y Performance:
-71.64%
1-Day Range:
$3.71
$4.04
1-Week Range:
$3.71
$4.45
52-Week Range:
$3.51
$16.95
Karyopharm Therapeutics Inc Stock (KPTI) Company Profile
Name
Karyopharm Therapeutics Inc
Sector
Industry
Phone
617-658-0600
Address
85 WELLS AVENUE, NEWTON, MA
Compare KPTI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
KPTI
Karyopharm Therapeutics Inc
|
3.93 | 32.92M | 140.46M | -146.34M | -117.73M | -1.27 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.13 | 117.32B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.87 | 58.89B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
401.80 | 51.14B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
673.80 | 41.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
299.01 | 32.59B | 3.81B | -644.79M | -669.77M | -6.24 |
Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-16-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Jul-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-19-23 | Initiated | Piper Sandler | Overweight |
| Nov-04-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Feb-09-22 | Upgrade | JP Morgan | Underweight → Neutral |
| Nov-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-06-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Aug-06-21 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-06-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jul-02-20 | Initiated | Morgan Stanley | Overweight |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-17-20 | Downgrade | Wedbush | Outperform → Neutral |
| Jul-23-19 | Upgrade | JP Morgan | Neutral → Overweight |
| Jul-05-19 | Reiterated | H.C. Wainwright | Buy |
| Jul-05-19 | Reiterated | Robert W. Baird | Outperform |
| Mar-01-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-28-19 | Reiterated | BofA/Merrill | Underperform |
| Feb-27-19 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jan-03-19 | Upgrade | BofA/Merrill | Underperform → Neutral |
| Dec-03-18 | Initiated | B. Riley FBR | Buy |
| Nov-09-18 | Upgrade | Wedbush | Neutral → Outperform |
| May-24-18 | Downgrade | Wedbush | Outperform → Neutral |
| Apr-02-18 | Resumed | Leerink Partners | Outperform |
| Nov-15-17 | Resumed | H.C. Wainwright | Buy |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-08-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-30-16 | Upgrade | Jefferies | Hold → Buy |
| Aug-18-16 | Initiated | H.C. Wainwright | Buy |
| Jun-28-16 | Initiated | Robert W. Baird | Outperform |
View All
Karyopharm Therapeutics Inc Stock (KPTI) Latest News
KARYOPHARM THERAPEUTICS Earnings Preview: Recent $KPTI Insider Trading, Hedge Fund Activity, and More - Quiver Quantitative
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PR Newswire
Why is Karyopharm Therapeutics Inc. stock attracting strong analyst attentionLow Risk Watchlist That Work - jammulinksnews.com
What makes Karyopharm Therapeutics Inc. stock price move sharplyValue Investing Picks For Beginners - jammulinksnews.com
What institutional investors are buying Karyopharm Therapeutics Inc. stockAI Powered Strategy For Beginners - jammulinksnews.com
Published on: 2025-07-30 09:02:26 - metal.it
How Karyopharm Therapeutics Inc. stock reacts to Fed policy changesExpert Verified Stock Trade Ideas Backed by Data - beatles.ru
Karyopharm Therapeutics (KPTI) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo Finance
What makes Karyopharm Therapeutics Inc. stock attractive to long term investorsGrowth Based Stock Signal Screener Updated - metal.it
Karyopharm Shares Slide After Financing Efforts Stall, Strategic Review Underway - MSN
How many analysts rate Karyopharm Therapeutics Inc. as a “Buy”Invest smarter with expert trading signals - jammulinksnews.com
When is Karyopharm Therapeutics Inc. stock expected to show significant growthBest Dividend Data Feed To Watch Now - jammulinksnews.com
How strong is Karyopharm Therapeutics Inc. company’s balance sheetPost Market Review For 2025 - jammulinksnews.com
Has Karyopharm Therapeutics Inc. found a price floorDaily Market Momentum and Pressure Analysis - Newser
What is the risk reward ratio of investing in Karyopharm Therapeutics Inc. stockCapitalize on fast-moving stock opportunities - jammulinksnews.com
Is Karyopharm Therapeutics Inc. a growth stock or a value stockMaximize returns with strategic portfolio planning - jammulinksnews.com
How Karyopharm Therapeutics Inc. stock performs during market volatilityExplosive Growth Potential - Newser
Layoff Tracker: Adicet’s Pipeline Optimization Push Claims 30% of Workforce - BioSpace
What drives Karyopharm Therapeutics Inc. stock priceConsistently high returns - PrintWeekIndia
Karyopharm Therapeutics Inc. Stock Analysis and ForecastFast-track wealth growth - PrintWeekIndia
What analysts say about Karyopharm Therapeutics Inc. stockUnprecedented market success - Autocar Professional
How high can Karyopharm Therapeutics Inc. stock price go in 2025High-yield market plays - jammulinksnews.com
Triple Refractory Multiple Myeloma Market Forecast 2032: - openPR.com
Is Karyopharm Therapeutics Inc. a good long term investmentRapid wealth multiplication - jammulinksnews.com
Karyopharm Therapeutics Inc Stock (KPTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
0.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):